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Abstract  
Objective: Although ADHD is highly heritable, genomewide association studies (GWAS) have not yet identified 
any common genetic variants that contribute to risk. There is evidence that conduct disorder/aggression in those 
with ADHD indexes higher genetic loading and clinical severity. Here, we investigate whether common genetic 
variants considered en masse as polygenic scores for ADHD are especially enriched in those with comorbid 
conduct disorder.  
Method: Polygenic scores derived from an ADHD GWAS metaanalysis were calculated in an independent ADHD 
sample (452 cases 5,081 controls). Multivariate logistic regression analyses were employed to compare polygenic 
scores in the ADHD group and controls and test for higher scores in ADHD cases with comorbid conduct disorder 
vs. controls and vs. those without comorbid conduct disorder. Association with symptom scores was tested using 
linear regression.  
Results: Polygenic risk for ADHD, derived from the metaanalysis, was higher in the independent ADHD sample 
than in controls (p=0.010). Polygenic score was significantly higher in ADHD cases with conduct disorder 
compared to ADHD cases without conduct disorder (p=0.013). ADHD polygenic score showed significant 
association with comorbid conduct disorder symptoms. This relationship was explained by the aggression items 
(β=0.151, t=3.152, p=0.002).  
Conclusions: Common genetic variation is relevant to ADHD, especially in those with comorbid aggression. The 
findings suggest that the previously published ADHD GWAS metaanalysis contains weak but true associations to 
common variants, support for which falls below genomewide significance levels. The findings also highlight that 
aggression in ADHD indexes genetic as well as clinical severity.  
 
Introduction  
Attention Deficit Hyperactivity Disorder (ADHD) is an earlyonset highly heritable neurodevelopmental disorder, 
characterised by marked clinical heterogeneity and a preponderance of affected males (24). It has a complex 
genetic architecture, as is the case for most common disorders. Although associated rare variants have been 
identified (58), it has generally been considered that the most satisfactory explanatory model of inheritance is a 
multifactorial, polygenic liability threshold one, where the combined effects of multiple common genetic variants 
with environmental factors contribute to ADHD risk.  
With respect to common risk variants, there are no genomewide significant findings for ADHD (1, 9). Although it 
has been proposed that this simply reflects inadequate sample sizes (6, 10), others suggest the lack of findings is a 
consequence of psychiatric disorders, including ADHD, being explained mainly or solely by rare high penetrance 
variants (11). So far, for ADHD, rare variants in the form of copy number variants (CNVs) have been found to be 
associated (58), and studies show that other classes of rare mutations make some contribution to autism spectrum 
disorder (ASD) (1214), another childhoodonset disorder that strongly overlaps with ADHD (15). While the issue 
about the relative contributions of common and rare variants is very far from being empirically resolved, it has 
previously been shown through pathway analytic approaches that not only do both contribute to ADHD, they tend 
to act on similar functional classes of genes (6, 16).  
Given a contribution from both common and rare alleles (and presumably also alleles with intermediate 
frequencies), the multifactorial, polygenic liability threshold model predicts that forms of the disorder in groups of 
people less often affected (e.g. ADHD in females) or with more severe forms of the disorder should carry a greater 
genetic load, including greater enrichment of ADHD common risk alleles.  
The presence of conduct disorder in those with ADHD is known to index greater clinical severity (17). Previous 
twin and family studies have also shown that in those with ADHD, the presence of conduct disorder/symptoms 
indexes higher ADHD familial and genetic loading (1822). For example, the relative risk (RR) for ADHD in 
biological relatives of probands who have ADHD that is accompanied by Conduct Disorder (RR 9.5), is almost 
double that of relatives of those with ADHD alone (RR 5.4) (18). These studies suggest that in ADHD, the 
presence of conduct disorder likely indexes greater genetic load. Previously, it has only been possible to infer this 
indirectly by measuring recurrence rates in various classes of relatives, but recent developments now allow the 
component attributable to relatively common alleles to be estimated using genomewide molecular genetic data in 
the form of polygenic load (2325). In the present study, using ADHD polygenic risk scores derived from the largest 
published genomewide association metaanalysis (1), we set out to test in an independent sample whether ADHD 
accompanied by conduct disorder is characterised by greater enrichment of ADHD “risk alleles” and also to 
investigate the relationship between polygenic score and conduct disorder symptoms.  
 
Methods  
Subjects  
Participants for what we term in this study the “Cardiff Sample” were recruited from Child and Adolescent Mental 
Health Services or Community Paediatric outpatient clinics in the UK. The sample of 452 children met criteria for 
a lifetime diagnosis of DSMIIIR or DSMIV ADHD, confirmed by a research diagnostic assessment (26). Children 
with bipolar disorder, schizophrenia, ASD, Tourette’s syndrome, IQ<70 (assessed using the WISCIII/IV) (27, 28), 
epilepsy or any other neurological or genetic disorder were excluded. Written informed consent from parents and 
assent/consent from children was obtained for all individuals. The study protocol was approved by NorthWest 
England and Wales Multicentre Research Ethics Committees. The control sample comprised 5,081 individuals 
from the Wellcome Trust Case Control Consortium – Phase 2 (WTCCC2).  
 
Clinical measures  
For the Cardiff sample, ADHD diagnoses were confirmed using the Child and Adolescent Psychiatry Assessment 
(26), a research diagnostic interview undertaken with the child's parents. Interviews were completed by trained 
psychologists, supervised weekly by a child psychiatrist and a psychologist. Interrater reliability for diagnosis of 
ADHD subtype assessed using 60 cases, was excellent (κ=1.0). Information on symptom pervasiveness and school 
impairment in school was obtained using the Child ADHD Teacher Telephone Interview (29), the DuPaul (30) or 
Conner’s teacher rating scales (31).  
The Child and Adolescent Psychiatric Assessment or CAPA was also used to assess comorbid psychiatric 
disorders. Interrater reliability for parentrated conduct disorder symptoms was very good (intra class 
correlation=0.98). Summed scores for total number of DSMIV conduct disorder symptoms were obtained in 
addition to diagnoses. In line with previous studies and factor analyses (32, 33), aggressive (DSMIV conduct 
disorder criteria labelled as “aggression to people and animals”) and covert (DSMIV conduct disorder criteria 
labelled as “Destruction of property” or “Deceitfulness or theft”) symptom totals were generated (see Appendix 1 
for a full list of DSMIV aggressive and covert conduct disorder symptoms).  
Genotyping  
DNA was obtained through saliva and blood samples. Genotyping for cases was performed on the Illumina (San 
Diego, CA, USA) Human660WQuad BeadChip. Genotyping for controls was performed using the Illumina 
Human 1.2M BeadChip. The samples, quality control assessment, and GWAS results are described in detail 
elsewhere (6).  
Published data used to derive ADHD polygenic risk scores  
We made use of the international metaanalysis of ADHD vs. control data described in detail elsewhere (1). This 
data set contains 2,064 trios, 896 cases and 2,455 control individuals and 1,206,461 single nucleotide 
polymorphisms (SNPs). Cases had been assessed with the same inclusion criteria and similar methods to the cases 
in the Cardiff study. A total of 54 individuals affected with ADHD were removed from the Cardiff sample as they 
had been included in the metaanalysis (1). Control groups were not overlapping.  
Polygenic Analysis  
We used the analytic approach described by the International Schizophrenia Consortium (25) with the published 
metaanalysis of ADHD (1) as the discovery data set and Cardiff sample ADHD data as the target set. Each 
individual in the target set was assigned a polygenic score, based on information in the discovery set. We made 
comparisons between ADHD cases (with and without conduct disorder) and controls to determine whether the 
ADHDderived polygenic scores were significantly different. As comorbid conduct disorder indexes higher ADHD 
familial loading, our key aim was to test whether polygenic scores for ADHD were higher in ADHD cases with vs. 
without conduct disorder.  
 
We first selected a set of SNPs in relative linkage equilibrium in our ADHD and control samples using a sliding 
window of 200 SNPs, moving it along the genome in steps of 5 SNPs and dropping a SNP when the pairwise 
estimate of linkage disequilibrium (r
2
) was greater than 0.2 (PLINK command: indeppairwise 200 5 0.2) (34). In 
the discovery metaanalysis data set, we identified corresponding pvalues and associated alleles for the selected 
SNPs. Based on the findings from the International Schizophrenia Consortium (25) and Psychiatric Genetics 
Consortium (23, 24), which identified a relaxed p<0.5 as the optimal ‘association’ threshold in discovery samples 
of the size equivalent to those used here, we a priori defined this as the threshold from which to derive score alleles 
from our discovery sample. Alleles that are more common in the discovery cases at p<0.5 for twotailed pvalues are 
termed the “score” alleles (34). For each individual in the target sample, we used PLINK (34) to obtain a polygenic 
score which corresponds to the mean number of score alleles across the set of SNPs. We employed logistic 
regression analysis to compare the polygenic scores for ADHD in the target set to the controls. To allow for 
population stratification in our data, we conditioned on two covariates (the first two principal components 
estimated from our GWAS data using EIGENSTRAT software designed for this purpose (35, 36)). We are priori 
hypothesised that ADHD “risk alleles” derived from the published GWAS would be enriched in our independent 
ADHD sample (compared to controls), and in particular in those with conduct disorder. Therefore for each analysis 
we report a onetailed pvalue and pseudoR
2
, the latter being a measure of the estimated variability in casecontrol 
status explained.  
Using logistic regression analysis, we then compared polygenic score in those with and without a conduct disorder 
diagnosis from the set of ADHD cases (ADHD with conduct disorder vs. ADHD without conduct disorder).  
Linear regression analyses were used to investigate whether polygenic score was significantly associated with total 
DSMIV conduct disorder symptom score, as well as aggression and covert conduct disorder symptom scores (see 
Appendix 1 for a list of the items). Our rationale for further dividing conduct disorder symptoms into two 
subgroups was based on factor analyses (33), showing that they can be split into aggressive symptoms (such as 
cruelty to people or animals, fighting and stealing with confrontation of the victim) and covert symptoms (such as 
firesetting, breaking into a building or car, or vandalism).  
 
Results  
A total of 452 children from the Cardiff sample met inclusion criteria and had genetic and phenotypic data 
available. They were aged 617 years (mean=10.7 years, SD=2.8 years), of whom 389 were male (86.1%) and 63 
were female (13.9%). The mean full-scale IQ was 87.13 (SD=11.24). The gender ratio and IQ scores are typical of 
UK ADHD clinic cases. The mean number of ADHD symptoms was 14.68 (SD=2.87, 25
th 
percentile ADHD score 
=13.00, 50
th
 percentile=15.00 75
th
 percentile=17.00). Within this sample, 77 (17.0%) individuals had a diagnosis 
of ADHD with conduct disorder and 375 (83.0%) had no comorbid conduct disorder. The mean numbers of DSM-
IV conduct disorder symptoms were 3.60 (SD=1.86) and 0.53 (SD=0.76) for the ADHD groups with conduct 
disorder and without conduct disorder, respectively. There was no association between conduct disorder scores, 
age and gender. In addition, 229 (50.7%) subjects met criteria for a DSMIV diagnosis of Oppositional Defiant 
Disorder; 65 of those with a conduct disorder diagnosis (84.4%) also had a diagnosis of Oppositional Defiant 
Disorder. A comorbid diagnosis of anxiety disorder was present for 22 individuals (4.9%) whilst comorbid 
depressive disorder was present in 3 individuals (0.66%).  
Polygenic scores predicting ADHD in the target sample  
ADHD risk as defined from weakly associated alleles (n=46,156) in the discovery GWAS was significantly higher 
in ADHD cases than controls (p=0.010) (Table 1). Thus, as we postulated, risk for ADHD is in part attributable to 
common alleles tagged by the genomewide genotyping arrays.  
Polygenic score enrichment in those with ADHD accompanied by conduct disorder  
The polygenic score representing ADHD risk was significantly higher in ADHD cases with a conduct disorder 
diagnosis compared to ADHD cases without conduct disorder (p=0.013). The magnitude of the effect (as defined 
by R
2
) was 1.1%, larger than that observed when comparing ADHD cases and controls (Table 1).  
To test if our findings could be attributable to higher ADHD total symptom count in those with conduct disorder, 
we tested association between ADHD symptom count and polygenic risk score. Within ADHD cases, the total 
number of ADHD symptoms was not significantly associated with polygenic score (β=0.018, t=0.374, p=0.709). 
As expected, total ADHD scores were significantly associated with total conduct disorder scores (β=0.159, t=-
2.900, p=0.004). ADHD polygenic risk scores were significantly higher in female cases than male cases (β=0.104, 
t=2.159, p=0.031) and thus all the data were reanalysed allowing for sex as a covariate. The results were 
unchanged (data not shown).  
 
Polygenic score predicting conduct disorder symptom scores  
Within cases, ADHD polygenic risk scores increased with total conduct disorder scores (β=0.118, t=2.530, 
p=0.006). At the level of individual composite phenotypes, they also increased with aggressive conduct disorder 
symptoms (β=0.151, t=3.152, p=0.002), but not covert conduct disorder symptoms (β=0.045, t=0.922, p=0.357). 
These associations remained significant when controlling for sex. The distribution of risk scores showed 
increasing polygenic score with respect to increasing total conduct scores (Figure 1).  
Discussion  
We initiated this study to investigate the contribution of common genetic variants to ADHD and to test whether 
comorbid conduct disorder, defined categorically and dimensionally, indexed greater genetic risk at a molecular 
level. Our data support a polygenic component to ADHD, in that the risk score was higher in our independent 
sample of ADHD cases than the controls. This is the first report to suggest that the previously published ADHD 
GWAS metaanalysis (1) harbours common risk alleles that do show contribution to ADHD, when they are 
considered en masse. More importantly, as studies which suggest that comorbid conduct disorder indexes higher 
familial and genetic loading in ADHD, we found that ADHD risk score is particularly elevated in those with 
ADHD and conduct disorder compared with those who have just ADHD.  
A withincase analysis of conduct disorder symptoms as a dimension rather than a category revealed similar 
findings, there being a positive linear relationship between ADHD polygenic scores and comorbid conduct 
disorder symptoms. Interestingly, this association related to aggressive, rather than covert, conduct disorder 
symptoms (see Appendix 1). Twin studies also suggest that these different symptom dimensions may be distinct in 
their genetic aetiology, with stronger genetic loading for overt aggressive symptoms (32, 37).  
Overall, our study confirms the hypothesis that common genetic variants are relevant to ADHD risk. The findings 
of the present study also highlight that comorbid conduct disorder indexes heterogeneity in terms of genetic 
loading at a molecular level. Our findings that individual symptom groups of total conduct disorder scores and 
aggressive conduct disorder scores are significantly associated with polygenic score further underscore the point 
that specific clinical phenotypes can index differential genetic loading. Most of the evidence to date suggests that 
conduct problems index ADHD cases that are quantitatively rather than qualitatively different from the remaining 
ADHD cases (38), in terms of the patterns of association with clinical, cognitive, genetic and environmental 
correlates. This is in keeping with the approach currently taken by ICD10, where Hyperkinetic conduct disorder is 
considered a subtype of ADHD/Hyperkinetic Disorder (39). However, some associated factors also appear to be 
unique to conduct disorder in ADHD. Notably, the functional COMT Val158Met variant has been found to be 
associated with conduct problems in ADHD (40), a finding that has been replicated in six independent samples (32, 
4143), while metaanalysis shows that this variant is not associated with ADHD risk (44). A separate future 
question of interest would be to investigate the independent contribution of genetic liability associated with 
conduct disorder (regardless of ADHD). There is evidence to suggest shared liabilities but as yet, large scale 
Conduct Disorder GWAS data sets are unavailable.  
We also incidentally found that female cases had significantly higher ADHD risk scores than male cases. This 
finding requires replication, but is intriguing as it supports the hypothesis that ADHD is less common in females 
because a more extreme genetic load is required for the liability threshold to be surpassed. This would predict that 
relatives of female ADHD probands have a greater risk for ADHD than relatives of male ADHD probands, 
although evidence here is lacking (4). However, there is the possible impact of ascertainment bias. Females with 
ADHD may be less likely to be diagnosed (or referred for diagnosis) than males with comparable severity of 
disorder (45) and therefore our findings might simply reflect that females must have more severe forms of the 
disorder to be diagnosed and ascertained. However, females in our sample did not have significantly more ADHD 
(p=0.919) or conduct disorder symptoms (p=0.511) than males.  
As expected, ADHD severity (i.e. total ADHD scores) showed association with conduct disorder scores, but the 
genetic findings were driven by conduct disorder as there was no association between ADHD severity and 
polygenic risk. As all clinical cases have high ADHD scores by definition, and thus variance is limited, this may 
not be surprising.  
It is of note that casecontrol comparisons were significant for the total ADHD group and the ADHD with conduct 
disorder group but did not achieve significance in the ADHD without conduct disorder group. This might simply 
reflect sample size, whereby groups with lower genetic load (those with ADHD without conduct disorder) would 
need larger samples than those with higher genetic load (those with ADHD with conduct disorder) to demonstrate 
statistically significant differences.  
This paper utilised a wellcharacterised sample of children who underwent careful phenotyping. The diagnosis of 
ADHD was confirmed using a semistructured research diagnostic interview, which also enabled detailed 
information to be obtained on conduct disorder symptoms and measures showed high reliability. There are no 
means of obtaining clinical data on the controls, although failure to exclude controls with ADHD or conduct 
disorder would reduce our power, not generate false positives. One limitation of casecontrol and within-case 
studies is the possibility of population stratification. However, we limited the impact of stratification by the well-
accepted approach of including derived principal components that allow for population variation (35, 36) in our 
ADHD GWAS, and by using hypothesisdriven analyses. Furthermore, for stratification to be an issue, it would 
have to be refractory to inclusion of the principle components and the same uncorrected ethnic variation be 
overrepresented in the cases in both the Cardiff sample and the samples used in the metaanalysis (46), and would 
also have to be specifically overrepresented in those with comorbid conduct disorder compared with the full 
ADHD sample.  
The magnitudes of the plygenic effect (as defined by R
2
) are small, as typically found using this method. The 
magnitude is also smaller than some figures published for schizophrenia (R
2
=3 to 6% (24, 25)) but not all (47). This 
method is also very sensitive to sample sizes and available GWAS data sets for ADHD are very much smaller than 
is the case for schizophrenia. In the most recent schizophrenia analysis (24) of over 9,000 cases and 12,000 control 
individuals, the total amount of variance explained was estimated to be 6%, whereas in an earlier analysis of 3,000 
cases and 3,000 control individuals by the International Schizophrenia Consortium (25), the estimate was 3%. Our 
estimate of percentage variance explained of 0.1% is based on a much smaller sample size of 452 ADHD cases and 
5,081 control individuals. Another factor that would reduce explained variance is heterogeneity across samples. 
This could plausibly be higher for some disorders than others; for example, through international differences in 
clinical service provision and thus, ascertainment as well as other variability such as ethnic composition. It is also 
important to note that GWAS SNP arrays do not completely capture relevant genetic variation; they “tag” 
potentially causal variants and the arrays do not capture the full spectrum of allelic frequencies or allele types (e.g. 
repeat sequence polymorphisms such as variable number tandem repeats). Overall, we expect that as more ADHD 
and control samples with more comprehensive genetic capture become available, more variance will be explained. 
Finally, we also acknowledge the contribution of environmental risk factors and gene-environment interplay, 
although this was not the focus of the present analyses.  
 
These findings suggest that ADHD, like other psychiatric disorders, can be considered a polygenic disorder, the 
architecture of which includes common as well as rare alleles (10). They are also compatible with our earlier work 
showing overlap between the biological processes enriched for weak ADHD SNP association signals and those 
enriched for rare copy number variants (6). Given the evidence for contribution of common variants, the future 
acquisition and genetic analysis of much larger ADHD samples in an attempt to capture relevant genetic variation 
is crucial. The aim is not to simply identify single “significant” SNPs of small effect size, but rather to utilise the 
spectrum of associated common and rare genetic risk variants to uncover novel clues for risk mechanisms and 
underlying biology and to inform our conceptualisation of ADHD.  
In conclusion, common genetic variation appears relevant to ADHD and a higher loading for common ADHD 
genetic risk variants is indexed by comorbid conduct disorder, especially aggressive symptoms. We also provide 
support that the previously published ADHD GWAS metaanalysis contains true associations to common variants, 
support for which falls below currently accepted genomewide significance levels. The findings highlight that 
aggression in ADHD, as an index of clinical severity, is underpinned by higher genetic loading at a molecular 
level. They also illustrate, that for hypothesisdriven research, careful phenotyping is still useful in psychiatric 
genetic studies.  
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Table 1: Summary of results using the published ADHD metaanalysis (1) as the discovery data and the Cardiff 
data set as the target sample. In all analyses, the ADHD cases had more risk alleles than the controls. +CD: 
diagnosis of conduct disorder, CD: no diagnosis of conduct disorder. All zstatistics are distributed with one degree 
of freedom and all pvalues are onetailed.  
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Comparison Analysis (Sample 1 vs. 
Sample 2)  
Sample sizes  
z-statistic  R2 (%)  p-value  
Sample 1   Sample 2  
ADHD sample 
ADHD+CD 
ADHDCD 
ADHD+CD  
Controls Controls 
Controls ADHD-
CD  
452 vs. 5081 
77 vs. 5081 
375 vs. 5081 
77 vs. 375  
2.32 3.11 
1.27 2.23  
0.098 
0.19 
0.030 
1.1  
0.010 
0.00095 
0.10 
0.013  
 
Figure 1: Box plot showing the distribution of polygenic scores for ADHD by total conduct disorder score. The 
whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range from the 
box.  
 
